Targovax ASA ( (GB:0RIS) ) has shared an update.
Circio Holding ASA has announced the conversion of NOK 1,500,000 worth of convertible bonds into 2,500,000 new shares, increasing the company’s share capital. This move, involving Atlas Special Opportunities, LLC, reflects Circio’s strategic financial management and could potentially enhance its market position by providing additional capital for its innovative biotechnology projects.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing next-generation RNA technology for nucleic acid medicine. They have created a unique circular RNA (circRNA) vector expression platform, known as circVec, which enhances protein expression and durability compared to traditional mRNA systems. This platform is applicable in various therapeutic settings, including genetic medicine and chronic disease. Additionally, Circio is working on a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations, with ongoing clinical trials in the USA and Norway.
YTD Price Performance: -93.95%
Average Trading Volume: 23,211
Technical Sentiment Signal: Strong Buy
Current Market Cap: NOK49.56M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.